Protalix BioTherapeutics (NYSE:PLX) Trading Down 7.1%

Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) dropped 7.1% during trading on Thursday . The stock traded as low as $1.02 and last traded at $1.04. Approximately 997,443 shares were traded during mid-day trading, an increase of 27% from the average daily volume of 783,997 shares. The stock had previously closed at $1.12.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 15th.

Protalix BioTherapeutics Stock Down 7.1 %

The firm’s 50-day moving average price is $1.17 and its 200-day moving average price is $1.36. The company has a market cap of $76.25 million, a P/E ratio of 26.00 and a beta of 0.78.

Protalix BioTherapeutics (NYSE:PLX) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $3.75 million during the quarter. Protalix BioTherapeutics had a net margin of 11.48% and a return on equity of 19.48%. As a group, analysts forecast that Protalix BioTherapeutics, Inc. will post 0.12 earnings per share for the current year.

Institutional Trading of Protalix BioTherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bailard Inc. purchased a new position in Protalix BioTherapeutics in the 4th quarter worth approximately $121,000. Virtu Financial LLC purchased a new position in Protalix BioTherapeutics in the 1st quarter worth approximately $198,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Protalix BioTherapeutics by 45.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 167,536 shares of the company’s stock worth $278,000 after buying an additional 51,997 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Protalix BioTherapeutics in the 3rd quarter worth approximately $825,000. Institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.